Nuwellis Introduces New 24-Hour Aquadex(TM) Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management
MWN-AI** Summary
Nuwellis, Inc., a prominent player in fluid management, announced the upcoming launch of its new 24-hour Aquadex™ circuit, set to debut in the U.S. this fall. This innovative circuit is specifically tailored for outpatient sessions, providing a single-day therapy setup to complement the existing 72-hour option used primarily for inpatient care. This strategic expansion aims to enhance the delivery of consistent fluid management across various healthcare settings, particularly as hospitals increasingly develop outpatient Aquadex programs that allow for fluid removal without the need for full hospital admissions.
John Erb, the CEO and Chairman of Nuwellis, emphasized the significance of the 24-hour circuit in facilitating a more straightforward and efficient pathway for outpatient care. This development stands to streamline scheduling and operational planning for healthcare providers, promoting more efficient clinic operations while expanding patient access to much-needed Aquadex therapy. The company also provides valuable resources to assist hospital-based outpatient sites, including training, implementation guidance, and patient identification tools.
The Aquadex SmartFlow® system, integral to Nuwellis's offerings, provides clinically validated ultrafiltration therapy to patients experiencing fluid overload, known as hypervolemia. It is particularly beneficial for patients who do not respond to traditional medical interventions. The system allows healthcare providers to administer treatment in both inpatient and outpatient settings, ensuring high-quality care.
Overall, the introduction of the 24-hour Aquadex circuit is poised to enhance care delivery for patients requiring fluid management and reinforce Nuwellis's position in the medical device market, as they continue to focus on innovation and patient-centered solutions. Further details on Nuwellis and its products can be found on their official website.
MWN-AI** Analysis
Nuwellis, Inc. (Nasdaq: NUWE) recently unveiled its 24-hour Aquadex™ circuit designed for outpatient fluid management, a strategic move that shows promise in an evolving healthcare landscape. This innovative offering aligns with the current trend toward outpatient care, which aims to enhance patient accessibility while lowering hospital costs. Given the growing demand for efficient fluid management—particularly in outpatient settings—this could serve as a significant growth driver for Nuwellis.
The introduction of the 24-hour circuit complements Nuwellis’ existing 72-hour option, presenting hospitals with versatile solutions for fluid overload treatment. By facilitating same-day outpatient therapy, Nuwellis is addressing a pressing need in healthcare that prioritizes patient convenience and operational efficiency. This dual approach not only simplifies scheduling and program management for providers but also fortifies Nuwellis’ standing as a key player in the fluid management market.
Investors should note that the company is proactively supporting hospital-based outpatient clinics with necessary resources such as patient identification and staff education, effectively expanding its market reach. This support may further accelerate the adoption of Aquadex therapy, positioning Nuwellis advantageously against competitors.
However, potential investors must also keep in mind the cautions associated with future growth. Market acceptance, funding for operational expansion, and competition from other innovations in the fluid management space are critical factors that could impact Nuwellis’ trajectory.
Overall, while the launch of the 24-hour Aquadex circuit presents exciting opportunities, thorough due diligence is warranted. Investors should monitor performance metrics and industry developments closely as Nuwellis positions itself to meet the increasing demands of outpatient care. A strategic buy recommendation could be considered for those with a long-term vision, particularly as this market segment continues to evolve.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MINNEAPOLIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., a fluid management company, announced plans to introduce a new 24-hour circuit for Aquadex therapy in the United States this fall. The new circuit is designed for single-day outpatient sessions and complements the company’s existing 72-hour option that is commonly used for multi-day therapy or inpatient care. Together, these options help hospitals match supply to setting while maintaining a consistent therapy experience.
Hospitals are building outpatient Aquadex programs to deliver predictable, scheduled care for patients who need fluid removal without a hospital admission. The 24-hour circuit supports that model by aligning with single-visit workflows, easing scheduling, and program planning. For patients, the goal is a straightforward same-day visit. For providers and administrators, the aim is a reliable pathway to run more efficient clinics and scale capacity.
“Hospital-based outpatient Aquadex therapy is growing as a reliable option for patients who need fluid removal without a hospital admission. The 24-hour circuit supports that model with a straightforward single-visit pathway,” said John Erb, Chairman of the Board and Chief Executive Officer of Nuwellis. “This addition is about meeting sites where they are, helping teams expand access to Aquadex therapy in a clinic setting and supporting consistent, high-quality care across both outpatient and inpatient programs.”
Nuwellis provides program resources for hospital-based outpatient sites, including patient identification, implementation guidance, and staff education to help teams add or expand Aquadex therapy in ambulatory settings.
For more information, visit www.nuwellis.com .
About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow ® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or X, formerly known as Twitter.
About the Aquadex SmartFlow ® System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2025 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
Jenene Thomas
JTC Investor Relations
NUWE@jtc.com
Media Contact:
Leah McMullen
Director of Communications
Leah.mcmullen@nuwellis.com
FAQ**
What specific market opportunities does Nuwellis Inc. (NUWE) anticipate with the introduction of the new 24-hour Aquadex therapy circuit, and how does this align with the current outpatient care trends?
How does Nuwellis Inc. (NUWE) plan to address potential challenges related to physician acceptance and competitive product offerings for the new 24-hour Aquadex circuit?
What strategies will Nuwellis Inc. (NUWE) employ to enhance staff education and implementation guidance for hospitals adopting the new outpatient Aquadex therapy?
In light of the forward-looking statements, how does Nuwellis Inc. (NUWE) intend to mitigate risks related to funding and product commercialization tied to the expansion of the Aquadex therapy?
**MWN-AI FAQ is based on asking OpenAI questions about Nuwellis Inc. (NASDAQ: NUWE).
NASDAQ: NUWE
NUWE Trading
-3.52% G/L:
$1.2832 Last:
25,984 Volume:
$1.36 Open:
